Research programme: antibodies therapeutics - Immune-Onc Therapeutics

Drug Profile

Research programme: antibodies therapeutics - Immune-Onc Therapeutics

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Immune-Onc Therapeutics
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 28 Mar 2017 Immune-Onc signs licensing and collaboration agreement with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center for developing novel biotherapeutics with applications in cancer immunotherapy
  • 01 Sep 2016 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top